International Assets Investment Management LLC Acquires Shares of 1,754 Neurocrine Biosciences, Inc. $NBIX

International Assets Investment Management LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 1,754 shares of the company’s stock, valued at approximately $220,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. Geneos Wealth Management Inc. increased its stake in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at $32,000. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at $34,000. SVB Wealth LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at $35,000. Finally, Golden State Wealth Management LLC increased its stake in shares of Neurocrine Biosciences by 116.9% in the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company’s stock valued at $44,000 after buying an additional 214 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on Neurocrine Biosciences in a research note on Thursday, July 10th. They issued a “buy” rating and a $182.00 target price for the company. Royal Bank Of Canada raised their target price on Neurocrine Biosciences from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Wednesday, October 8th. Citigroup began coverage on Neurocrine Biosciences in a research note on Tuesday. They issued a “buy” rating and a $175.00 target price for the company. Finally, Stifel Nicolaus lifted their price objective on Neurocrine Biosciences from $166.00 to $174.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $164.32.

Insider Activity

In other news, Director Kevin Charles Gorman sold 106,322 shares of the business’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the completion of the transaction, the director directly owned 514,596 shares in the company, valued at approximately $65,050,080.36. The trade was a 17.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Trading Up 1.6%

Neurocrine Biosciences stock opened at $143.67 on Friday. The firm has a market capitalization of $14.25 billion, a P/E ratio of 42.51, a PEG ratio of 1.00 and a beta of 0.21. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $154.61. The business has a 50-day moving average of $139.71 and a 200-day moving average of $127.13.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.08. The company had revenue of $687.50 million during the quarter, compared to analyst estimates of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.63 EPS. Research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.